

UPDATED

Flow Cytometry Panel for Myelodysplastic Syndrome

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic disorder. Traditionally, the gold standard for the diagnosis is based on morphologic evaluation and cytogenetic analysis, in conjunction with clinical findings. However, the morphologic findings in MDS can vary greatly and only 25-65% of the cases demonstrate cytogenetic abnormalities. Therefore the diagnosis is often difficult.

Recently, refined definitions and standards in the diagnosis and treatment of MDS were proposed in a report from an international working conference in Vienna convened in 2006. In the proposed minimal diagnostic criteria, flow cytometric analysis of bone marrow cells in MDS is introduced as a co-criterion. We believe that it is necessary to update our MDS flow cytometry panel to gain more diagnostic and prognostic information. Following is the updated panel.

TUBE	FITC	PE/RD1	ECD	PC5	PC7
1	CD34	CD19	CD10	CD117	CD45
2	CD235A	CD71	HLA-DR	CD34	CD45
3	CD16	CD13	CD14	CD11B	CD45
4	CD15	CD33	CD10	CD64	CD45
5	CD7	CD56	CD5	CD2	CD45

References:

1. Stachurski D, et al., Leuk Res. 2007 Jul 31 [Epub ahead of print]
2. van de Loosdrecht AA, et al., Blood 2008, 111(3):1067-77.
3. Loken M, et al., Leuk Res 2008, 32:5-17
4. Valent P, et al., Leuk Res 2007, 31:727-36.
5. Lorand-Metze I, et al., Leuk Res. 2007, 31(2):147-55.

Please forward this to appropriate staff members within your facility. If you have any questions, please contact CML at (402) 280-4382.

Creighton Medical Laboratories is proud to be your partner in providing effective and timely health care.

